Table 3—

Albuminuria and renal outcomes in type 2 diabetes

Number of patientsStudy populationMean follow-upInterventionRenal risk with albuminuria
IDNT (5,10,47)1,715Type 2 diabetes, hypertension4 yearsIrbesartan, amlodipine, or placebo
  • HR 2.04; 95% CI 1.87–2.22

  • Each 50% decrease in proteinuria in the first 12 months: reduction in renal risk (HR 0.44; 95% CI 0.40–0.49

RENAAL (3,7,9,48)1,513Type 2 diabetes3.4 yearsLosartan (50 mg or 100 mg) vs. placebo
  • HR 6.2; 95% CI 4.4–8.7

  • Each 50% decrease in albuminuria in the first 6 months: reduction in risk for end-stage renal disease of 45%

MARVAL (49)332Type 2 diabetes6 monthsValsartan vs. amlodipine
  • Urinary AER at 24 weeks was 56% (95% CI 49.6–63.0) of baseline with valsartan and 92% (95% CI 81.7–103.7) of baseline with amlodipine

IRMA-2 (11)590Type 2 diabetes, hypertension2 yearsIrbesartan (150 mg or 300 mg) vs. placebo
  • HR for progression to overt nephropathy: in the 150 mg group: HR 0.56, 95% CI 0.31–0.99; in the 300 mg group: 0.32, 95% CI 0.15–0.65)